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Abstract: High levels of adherence in clinical trials are essential for producing accurate 
intervention efficacy estimates. Adherence to clinical trial products and procedures is dependent 
on the motivations that drive participants. Data are presented to document reasons for trial 
participation and adherence to daily aciclovir for HSV-2 and HIV-1 genital shedding suppres-
sion among 300 HIV-1/HSV-2 seropositive women in South Africa. In-depth interviews after 
exit from the trial with 31 randomly selected women stratified by age and time since HIV 
diagnosis confirmed high levels of adherence measured during the trial. Main reasons for trial 
participation were related to seeking high-quality health care, which explains high levels of 
adherence in both study arms. Concerns that women would abuse reimbursements, fabricate 
data, and share or dump pills were not corroborated. Altruism is not a primary motivator in 
these settings where access to quality services is an issue. This study provides further evidence 
that good adherence of daily medication is possible in developing countries, particularly where 
study activities resonate with participants or fill an unmet need.
Keywords: adherence, trial, HIV prevention, South Africa
Introduction
Much of the limited efficacy of recent biomedical HIV prevention trials has been 
attributed to suboptimal adherence among trial participants.1 Concerns have been 
raised about participation in clinical trials being driven by reimbursement and that 
pill dumping or sharing might be rampant in communities underserved by the formal 
health sector. Such motivations for participation might negatively impact on study 
adherence. Little research has been conducted to investigate the motivation driving 
participants to take part in HIV prevention, as opposed to HIV treatment research trials 
in low and middle income countries, and the impact this may have on trial adherence 
and the validity of trial findings.
In this scant literature, altruism and access to personal health and behavioral benefits 
have been recorded as the dominant reasons for participation in trials.2–4 Compensation 
was noted as important among Kenyan participants in HIV/AIDS trials5 and among 
vaccine trial participants in the US, Canada, and the Netherlands, although it was not 
one of the main reasons for participation.2 Gender differences for trial participation 
have been found, with women more likely than men to participate in trials for a broader 
range of reasons, including access to protection, services, or compensation.2 In lower 
and middle income countries there are particular concerns that compensation may 
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drive trial participation and that this motivation may have 
negative consequences for adherence.
The results of clinical trials for HIV prevention are 
dependent on high levels of adherence, which has proven 
problematic for a number of prevention strategies tested thus 
far.6 There are three components to adherence in such trials: 
(1) adherence to study visits as a prerequisite for product/
intervention adherence; (2) adherence to specific products/
interventions being tested within the trial; and (3) adherence 
to additional practices required by the protocol (eg, the use of 
condoms, avoidance of vaginal douching, abstinence, etc).
Measurement of adherence is challenging. Traditionally 
product adherence has been measured through pill count and 
self-report. Biomedical markers are increasingly being used 
to monitor product adherence,7 but behavioral adherence 
continues to rely on self-reported data. Such data has inherent 
limitations associated with lack of participant cooperation, 
problems with recall, and social desirability bias.8
In this study we examined reasons for trial participation 
and the influence of this on subsequent adherence to study 
drug and procedures among female trial participants in 
Johannesburg, South Africa. Participants were HIV-HSV-2 
co-infected women not yet eligible for anti-retroviral therapy 
(ART) who were enrolled in a randomized, double-blinded, 
placebo-controlled trial to examine the efficacy of twice daily 
HSV-2 suppressive therapy with aciclovir in reducing HIV 
transmissibility.9 Through this study we hope to confirm high 
levels of trial adherence and how reasons for participation 
might influence this. This information may be useful in the 
design of future trials of HIV prevention interventions.
Methods
Study participants
Between April 2005 and April 2006, 300 HSV-2 and HIV 
seropositive women were enrolled in a trial and randomized 
to receive aciclovir 400 mg one tablet twice daily (n = 152) 
or matching placebo (n = 148), and followed up at monthly 
intervals for 3 months. Women had a mean age of 32 years 
and a 1 year median time since HIV diagnosis, and were 
compensated ZAR150 (approximately US$20) for each study 
visit. Trial outcomes have been reported elsewhere.9
In the current study, a 10% random subsample of trial 
participants from both study arms (n = 31) was recruited 
according to three criteria: age (women were selected from 
the 18–30 years and 31–60 years age groups); duration of 
HIV infection (whether women were aware of their status 
since #1 year or .1 year); and willingness to participate. 
Once trial exit visits were completed, contact information 
collected during the trial was used to establish interest in 
participating in an additional study visit and to set up inter-
view times with participants. Appointments were made for 
women to visit the clinic at a time suitable for them. At this 
visit, the objectives of the in-depth interview (IDI) visit were 
further explained and women provided written consent for 
their participation in the interview, as well as permission for 
their discussion to be tape recorded. Women were compen-
sated ZAR50 (approximately US$7) for their participation.
Trial procedures and quantitative  
data collection
During the trial, participants were seen at monthly clinic 
visits (visit interval 30–35 days) for a total of three visits, 
when drug packs were returned for pill count, a new supply 
of drugs dispensed, and data on self-reported adherence 
collected. At each visit, participants received adherence 
counseling which included instructions for study drug use, 
storage, and handling of missed doses.
All participants received pre- and post-test sexually 
transmitted infection (STI)/HIV counseling, regular risk 
reduction counseling, free condoms, treatment of STIs, and 
referral to local HIV treatment centers. All participants with 
symptoms of genital ulcers received presumptive treatment 
for genital herpes with aciclovir for 5 days, irrespective of 
study arm, in addition to the standard antimicrobial regimen 
of syndromic management. As required by the study  protocol, 
participants were counseled to avoid vaginal cleansing and 
unprotected sexual intercourse for 72 hours before their next 
clinic visit when genital samples were collected. Where 
sex was unavoidable, participants were encouraged to use 
a condom in order to avoid contamination of samples with 
semen. Free condoms were provided.
Qualitative data collection
Interviews were conducted face-to-face with a single female 
interviewer in local South African languages. The interviews 
lasted approximately 90 minutes and were tape-recorded. 
The interviewer used a semi-structured interview topic 
guide in which women’s reasons for participation and their 
adherence to various aspects of the study were examined. 
The interview topic guide was developed in English and 
reviewed by the interviewer and study investigators to ensure 
that meaning in local African languages was clear and that 
there was agreement on correct terminology for discussions. 
To ensure that participants were comfortable discussing the 
issue of trial adherence, data collection was conducted after 
each participant’s exit visit from the trial, once adherence 
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measures had already been calculated and participants were 
no longer on treatment. Additionally, women were assured of 
confidentiality and explicitly informed that their adherence 
issues would not be discussed with staff from the trial.
Qualitative data analysis
Recorded interviews were independently translated and 
transcribed into English. One of the investigators (CM) read 
through all transcripts to identify major themes.  Thereafter a 
coding frame was constructed using Atlas.ti (v 5.2;  Scientific 
Software Development, Berlin, Germany) and a line-by-line 
review of transcripts was conducted. Quotes were allocated 
to codes using a framework analysis approach.10 Text 
corresponding to each of the themes was grouped together 
and reviewed. Analysis continued as an iterative process 
through discussions and refining of the major themes. 
Sub-themes were then established using a method of constant 
comparison11 to break down higher-level codes (themes) 
into smaller categories within the framework. Quotes were 
selected for inclusion in the paper if they reflected dominant 
attitudes and actions or were good illustrations of counter 
normative behavior.
Ethical approval
The Human Research Ethics Committee (HREC) of the 
University of the Witwatersrand and the ethics review board 
of the London School of Hygiene and Tropical Medicine 
approved the trial. The trial was registered with the South 
African Department of Health national register of clinical 
trials (DoH-27-0207-1376). The qualitative interview was 
approved by the HREC as an auxiliary study to the trial 
(Reference: 061003).
Results
Reasons for participation in a clinical  
trial of HIV prevention
In order to begin understanding adherence in this trial, 
women were asked about their reasons for participation. The 
vast majority of participants first approached the clinic and 
became involved in the trial in an attempt to get information 
and to gain control of their health, regardless of the time 
since their HIV diagnosis.
[I came to the clinic] to get information – I came to the 
clinic to sort out my health. (Participant #15)
Working with women’s interest in their health, trial screen-
ing staff at the clinic encouraged women to investigate whether 
they were infected with HSV-2 and HIV. A number of women 
in the trial noted that the opportunity to establish whether they 
were HIV and HSV-2 seropositive were important motivators 
in their trial participation. These women had not necessarily 
experienced symptoms of either disease prior to screening and 
enrolment into the trial but were aware of the high prevalence 
of both in local communities, either prior to engagement with 
trial staff or after participation in screening health talks, and 
wanted to be sure of their own serostatus.
The reasons that I came here is that they told us that they 
are going to check us first if we do not have herpes. Then 
I thought it is better that I come because herpes is something 
that is not nice to have. The other thing is the sooner they 
find out that I have herpes, the sooner they will treat it. 
It is worse when you are HIV positive because there are 
many things that can happen without [you] knowing, like 
infections. (Participant #14)
The thing that made me decide to come here is because of 
family planning. Then I found the Community Health Worker 
talking down there in the family planning area and saying 
how it is important to do a [HIV] test and to come to check 
for herpes. Then I told myself to come and find out about 
my health because it is not good if I do not know what is 
going on with my health. (Participant #11)
Others noted that information on the trial was provided 
to them at the time that they had approached public sector 
clinics for STI treatment. These women were concerned 
specifically about their sexual health and used participation 
in the trial as a means to better understand the symptoms 
that they had.
The reasons to participate in the trial are because I heard about 
herpes and I used to have a rash in my vagina. Then I thought 
the treatment maybe would help me. (Participant #12)
The thing that made me decide to participate in the study 
was I started to see symptoms that I did not understand, like 
I had discharge and I was always sick so then I decided to 
go and find out about my status. (Participant #16)
A further group of women joined the trial already aware 
of the fact that they were either HIV or HSV-2 seropositive 
(or both). They noted that participation in the trial gave them 
the opportunity to better manage their illnesses and to obtain 
additional information about infection, treatment, and the 
prevention of transmission to others.
The first reason was that I wanted to check myself, what 
is my health like and I wanted them to treat me because 
I have herpes. Those were the reasons why I came to [clinic 
name]. (Participant #8)
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The people from [clinic name] came to [local community] 
and told us about the clinic so then I told myself that I must 
come to the clinic to find out more about my health. Even 
though I knew that I am HIV-positive but I wanted to know 
more about herpes. (Participant #25)
At the time of the trial, aciclovir was not available as 
first-line therapy for genital ulcers in the South African public 
health sector, and could only be obtained at considerable cost 
through the private sector. Among those women who noted 
that the potential for herpes treatment was a strong motivator 
for participation, a small subset particularly noted that free 
treatment had motivated their participation. Participant #4 
noted: ‘… they said after finding out that you have this virus 
they will give you free treatment.’
A strong motivator for trial participation among this 
group of HIV-positive women was the ability, through the 
trial procedures, to have monthly updates on their CD4 cell 
count. At the time of the trial, antiretroviral treatment of HIV 
was available free in the public health sector for patients 
with CD4 cell count below 200. Women who had known 
their HIV-positive status for more than 1 year were therefore 
particularly interested in participating in the trial to obtain 
more regular CD4 testing than would usually be available to 
them in the public sector, and thereby increase their chance 
of initiating HIV treatment as soon as they were eligible.
I have not been sick since I knew that I am HIV-positive but 
I know that if you are HIV-positive you must always check 
your CD4 count, you must not wait until your CD4 count 
goes down. I think that is the thing that made me decide to 
come and join the study even though they told me that they 
are doing research but I wanted to see if they were going 
to help me. (Participant #19)
Although women did discuss HIV and HSV-2 specifically 
during the interviews, they were more likely to speak of want-
ing to improve their health more generally. This reflects that 
women’s decisions to participate in this clinical trial were 
made independently of their diagnosis and reflect an attempt 
to address concerns with their health generally, rather than 
being specifically focused on HSV-2 and aciclovir. Although 
access to information and treatment dominated discussions, 
a small number of women discussed other motivations for 
trial participation, beyond access to improved health care.
The issue of receiving reimbursement was not a motivat-
ing factor for most women. In fact, only a single participant 
noted that reimbursement had affected her decision to par-
ticipate in the trial when she said that beyond the benefit of 
having her CD4 cell count monitored: ‘I would say money 
also helped me in addition to the other things that I was get-
ting here.’ (Participant #14). Indeed, if women did discuss the 
issue of reimbursement, it was more likely to be in the context 
of assuring the interviewer that money had not been part of 
their motivation for joining the study. Participant #20 stated: 
‘I joined the study because I wanted to know about my health, 
it was not because of money.’ This type of statement was 
echoed by a further participant.
My aim for coming to the clinic was to get something 
to help me. I found what I was looking for because the 
medication that I received helped with my problem. My aim 
was not to receive money when I came here. If it was just 
because I wanted money then it would have been better if 
I had just stayed at home. (Participant #16)
Altruism was also not a major determining factor in 
women’s trial participation. Most women displayed a good 
understanding of the concepts of research trials, randomiza-
tion, and placebo controls. The statement by Participant #19: 
‘I was wishing to get the one that they said it is the active one. 
Then I told myself that what about the nurse? She doesn’t 
even know which one is going to work. So I thought whatever 
I am going to get will be fine with me’ reflects the attitude of 
most women in the trial. Women reported feeling certain that 
whatever drug they received in the trial would assist them, 
although they understood that randomization and placebo 
drugs were a necessary component of the research process.
While this detailed understanding of the mechanisms 
of randomized placebo-controlled trials might suggest that 
women’s participation was motivated by altruism, only 
a single participant explicitly noted that her decision to 
participate was motivated by a desire to assist the research 
process. She explained:
The thing they told us is that they don’t know if it is working 
or not because they are still doing research, so I did not 
have a problem if it is not working because I wanted to help 
them to discover the information. (Participant #4)
Overall, women discussed their decisions to participate in 
the research process as a rational health decision in the face of 
general poor reproductive health in their local  communities. 
This is reflected by the fact that many of the women reported 
having discussed the trial with family and friends when mak-
ing their decision about participation.
My mother helped me to make the decision to come to the 
clinic. She told me that I must go – maybe it’s where I am 
going to get help, because I was starting to stress myself. 
(Participant #6)
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Women were most likely to have asked for opinions on 
participation from female relatives or friends, and while 
most reported that their partners were aware of their partici-
pation, few mentioned that their male partners had assisted 
them in deciding to participate in the study. Additionally, 
women specifically reported discussing trial participation 
with friends or family they knew were infected with HIV or 
HSV-2 in the hope that they too might make the decision to 
participate in the study.
I did tell people about the study; like that they do HIV and 
HSV-2 tests. The reason for me to tell them is that they 
have sores and that problem with their vaginas. I also 
told them that I used to have a sore in my vagina but 
since I have enrolled in the study all the sores are gone. 
(Participant #3)
There were some concerns about women being actively 
dissuaded from trial participation given the stigma surround-
ing HIV in South African communities and a degree of mis-
trust of medical research based on historical exploitation by 
the apartheid government and perceptions of profit motives 
of large pharmaceutical companies. However, most women 
interviewed here said that there were no individuals who 
had attempted to stop them from participating in the trial, 
although some noted that their partners had not supported 
their decision to enroll.
Interviewer: Did you have a problem with other people 
seeing you coming to the clinic?
Respondent: No, I did not think about that because you 
know as a person you must not think about what other 
people are going to say if they see you going to that clinic. 
(Participant #8)
Given that women perceived participation in the trial 
as an important and beneficial health intervention, most 
reported that they ignored negative attitudes from partners. 
Additionally, women did not appear to be concerned with 
being identified as trial participants. Indeed, many specifi-
cally said that the trial was about their health and that they 
would not have paid attention to anyone who had attempted 
to sabotage their participation.
Adherence to trial visits
HIV prevention trials in general and this trial specifically, 
have three adherence components. First, adherence to study 
visits; second, adherence to the study drug (in this case 
aciclovir or placebo); and third, adherence to particular 
behavioral requirements.
Visit adherence is an important component of study drug 
adherence because participants needed to visit the study 
clinic every month in order to receive new drug supplies 
and provide data on product adherence. During the trial, 
adherence to clinic visits was considered good. Overall, more 
than 90% of planned study visits were completed 541/604 
(90%) in the aciclovir arm and 545/592 (92.1%) in the pla-
cebo arm. During post-trial qualitative interviews, one-third 
of participants mentioned having missed scheduled visits, 
although most noted that they had made up the visit within 
the following week.
No reasons for missed visits emerged above all others; 
problems with work, childcare, travel plans, and simply 
forgetting were all mentioned.
Yes, I was supposed to come on Wednesday and then I did 
not come on that day, I came on the next day because my 
mother was not at home so there was no one to look after 
my baby. (Participant #15)
Two women mentioned that they had missed their sched-
uled visits due to menstruation. This was, however, a protocol 
requirement and was accommodated in the visit schedule. In 
general, women noted that there were few good reasons for 
missing clinic visits: visit schedules were known ahead of 
time and required sufficient planning. Such planning included 
having small children accompany them on study visits when 
necessary, ensuring that they had transport money on the 
day, and marking appointments on the calendar so that they 
were not forgotten.
The strongest factor encouraging clinic visit adherence 
was staff support. This was mentioned by more than half of 
the interviewees and was often repeated multiple times in 
individual interviews. Women consistently noted that the 
clinic staff had been friendly, concerned, and had provided 
guidance and assistance with problems beyond adherence 
to the study.
I think it [staff attitude] helped me because when I thought 
about coming to the clinic I knew that I am going to be 
laughing and talking to people who care about me and 
I loved to come to the clinic. (Participant #19)
Women commented on this particularly, given that they 
were HIV-positive and seemed to expect some degree of poor 
treatment from clinic staff, as illustrated by Participant #8 
who noted that ‘They [clinic staff] helped me because they 
managed to sit down with me and they said that this is not 
the end of the world, you can continue with your life and 
when I told them about my status they did not discriminate 
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against me or talk negatively about me.’ In addition, study 
staff assisted with adherence through reminder phone calls 
and flexibility around study visits when participants had 
scheduling conflicts.
As well as reminding participants about their medication, 
family were also an important source of encouragement for 
visit adherence, although this was discussed less frequently 
than as motivation for product adherence.
My sister used to encourage me and remind me about my 
date to come to the clinic … Everyone in my house used to 
encourage me to come to my study visits. (Participant #6)
Discussion of barriers to visit adherence was relatively 
limited, possibly as a result of the fact that women were 
interviewed when they had completed all study visits. The 
most significant barriers to participation were issues with 
transport (8/31 interviewees), with women citing poor trans-
port infrastructure and financial hardship as impediments to 
visit adherence, although most managed to borrow money for 
transportation costs knowing that they would be reimbursed 
after each clinic visit.
The thing is I had to borrow money for transport so that 
I can come to the clinic … when I get home I must pay the 
money that I borrowed before I came to the clinic by using 
the money from here. (Participant #17)
There was a transport problem because if I come here I must 
change taxis twice so that is a problem … It is far, but there 
is nothing that I can do about that. (Participant #23)
A further challenge that women perceived to their visit 
adherence was waiting times at the clinic (5/31 interviewees), 
despite this being vastly improved over normal waiting 
times in public health clinics. A small number of women 
also mentioned that their employment was a barrier to their 
participation in the trial (this in connection with long waiting 
times in the clinic). Most employed women were however 
accommodated, where possible, through early morning 
appointments and Saturday clinics.
Adherence to trial product
Pill counts were seen as a relatively objective means of 
measuring adherence to study product between visits, and 
adherence was calculated as the proportion of pills taken 
out of the total number of pills that should have been taken 
during the visit interval. Pill count measures provided a 
useful estimate of average adherence each month, but relied 
on participants to attend scheduled visits and to remember 
to returned used pill packs and remaining pills. Pill pack 
return rates (ie, the proportion of pill packs returned to the 
clinic out of those dispensed at the previous visit) were 
similar when comparing the aciclovir group with the placebo 
group at month 1 (96% vs 92%), month 2 (93% vs 96%), 
and month 3 (94% vs 92%).
In this trial, levels of .90% adherence to the product 
were desired. These levels of adherence were observed in 
the early trials of aciclovir where suppression of .80% 
of HSV-2 reactivation was achieved.12,13 It was thought 
that similar levels of adherence would be required to see 
an impact on HIV transmissibility. Using pill count as a 
measure, overall adherence was high, with a mean adherence 
rate of 95% in both study arms among those who returned 
their pill boxes.
In addition to pill counts, adherence was also measured 
by self-report. These complementary measures provided 
additional information on the number of consecutive 
doses (ie, one tablet twice a day) missed. HSV-2 has been 
shown to resume reactivation after 5 days of stopping 
HSV-2 suppressive therapy and so it was important to 
know about the number of consecutive doses missed in 
addition to an overall estimate of adherence by pill count.14 
At each visit, participants were asked about missed doses 
and reasons for this. Participants who reported missing 6 or 
more consecutive days at each of the monthly visits were 
considered to have lost any benefits of HSV-2 suppressive 
therapy. Overall, slightly more participants in the placebo 
arm compared to the aciclovir arm reported missing 6 or 
more consecutive doses at all visits except the exit visit 
(Table 1). The median number of doses reported as missed 
at each month was also higher among the placebo group. 
Forgetting to take pills, missing visits, and being away 
from home were the three most frequently reported reasons 
by women for missing doses in both treatment arms. Side 
effects were seldom reported as a reason for omitting to 
take drugs. Pill sharing was not reported as a reason for 
missed pills by participants (Table 1), although in a specific 
question about pill sharing, one participant who was in 
the placebo arm reported at her month 3 visit that she had 
shared ten pills with another person.
During the post-trial interview discussions about 
adherence, almost half of participants mentioned that 
they had missed some doses of their study drug. In most 
instances, specific reasons for missed doses were not pro-
vided and the number of missed doses was not detailed. In 
all cases, participants noted that they had missed ‘a couple 
of doses’ and had used various strategies to make up missed 
medication.
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It was alright and then there were some days where 
I forget to take my medication but not for such a long 
time. It happened that I would not take my medication 
in the morning but I will take two in the evening. 
(Participant #13)
The reasons for drug non-adherence provided in the inter-
views closely matched self-reported information collected 
quantitatively during the trial. In most instances participants 
noted that a change in routine and traveling were reasons for 
missed doses, as illustrated by Participant #20 who mentioned 
that ‘… traveling was the thing that mostly disturbed me in 
taking my pills.’ Other participants noted similar issues with 
being away from home.
I used to have a problem with taking my pills because I used 
to visit my boyfriend then I would often forget to take my 
pills with me. (Participant #27)
A small number of participants mentioned that they 
had experienced some negative health impacts that they 
attributed to the study drugs. One participant noted that 
the headaches she experienced during the trial prevented 
her from taking all doses but other side effects attributed to 
the study were minor and were not reported as impacting 
on adherence.
Half of the interviewees specifically noted that they had 
not missed any doses of study drug. There were no instances 
in which the participant noted both and this therefore seems 
an accurate representation of product adherence.
Yes, I did take my pills the way the way they told me to 
do. Like they said I must take one in the morning and one 
in the evening. So [name], the person who was working 
at the pharmacy told me that it’s better if you take both at 
the same time so I would not forget to take them … I never 
missed to take my treatment and I never missed my clinic 
visit. (Participant #15)
A small number of interviewees explicitly linked their 
motivation to adhere to study drugs to a perception that 
their health had improved since enrolment in the study and 
to ensuring that they experienced the health benefits they 
believed would accrue through taking the correct  dosage. 
Participant #9 mentioned the following: ‘I think it’s because 
I started to feel better and there were some changes so 
I continued taking the pills.’ This concern with health ben-
efits was reflected in participant comments about honesty 
in reporting adherence to clinic staff. Participants reflected 
that lying about their adherence would limit the degree to 
which they could measure health improvements or manage 
health problems.
I was honest because I wanted to know what was hap-
pening to me if I forgot to take my pills or whether I have 
improved or gotten worse [gained or lost something]. 
(Participant #16)
I think to lie is not good – it’s better you tell them the truth 
even if you forgot to take your pills. Moreover when you 
lie you are lying to yourself because if you did not take the 
pills and then if hide this without telling the nurse it means 
you are killing yourself. (Participant #19)
The study specifically examined whether pill sharing 
might account for poor adherence. Among the participants 
interviewed after the trial, no participants reported pill shar-
ing and many noted that it was an unwise strategy if one 
was concerned about one’s own health and that of partners, 
family, or friends. Participant #14 noted: ‘I did not share with 
anyone because if they give you some pills it is for you, not 
for other people.’
Participants reported a range of strategies that assisted 
them in maintaining adherence. Specifically, participants 
reported taking missed doses in the evenings (as detailed 
above) and particularly receiving support from family, 
friends, partners, and clinic staff.
Table 1 Self-reported adherence measures and reasons for 
missed doses in the trial
Aciclovir group 
N = 151
Placebo group 
N = 148
Missed six or more consecutive doses
 Month 1 
 Month 2 
 Month 3
17 (11%) 
11 (7%) 
11 (7%)
15 (10%) 
15 (10%) 
15 (10%)
Median number of doses missed (IQR)
 Month 1 
 Month 2 
 Month 3
6 (3–12) 
5 (2–8) 
3 (2–6)
4 (2–7) 
8 (3–16) 
16 (6–24)
Proportion of women reporting following reason for missing dosesa
 Missed visit 
 Forgot 
 Away from home 
 Change in routine 
 Lost pills 
 Experienced side effects 
 Illness 
 Shared pills with  
 another person 
 Other reason
21 (14%) 
44 (30%) 
15 (10%) 
2 (1%) 
0 
2 (1%) 
3 (2%) 
0 
 
1 (1%)
23 (16%) 
32 (23%) 
12 (8%) 
6 (4%) 
4 (3%) 
1 (1%) 
6 (4%) 
0 
 
4 (3%)
Note: aThis is a cumulative measure which represents the proportion of women 
who cited a particular category as the reason for missed doses in a particular month, 
summed over the 3-month period.
Abbreviation: IQR, interquartile range.
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I was honest because I told them [clinic staff] I was taking 
my pills and I was honest about it. The other thing is that 
I never missed to take my pills and my husband used to set 
the alarm so the time it started to go off I knew it was the 
time for me to take my pills. (Participant #19)
There were few instances in which participants mentioned 
other strategies for adherence other than assistance from 
family, partners, or clinic staff. One participant noted that she 
made sure to always carry the medication with her in her bag 
and another mentioned that she used her cell phone reminder 
function as an alarm for her scheduled medication.
Adherence to trial behavioral 
requirements
The trial protocol required that participants self-collect 
vaginal tampons and refrain from vaginal practices such as 
douching. Participants were also counseled about condom use 
for general safe sex, but particularly for sex acts immediately 
prior to study visits that might contaminate genital shedding 
samples. Most women in the study were experienced tampon 
users and most did not report douching prior to enrolment 
in the trial. In instances where women did practice douch-
ing or other vaginal cleansing processes, the explanations 
provided by study staff were viewed as sufficiently clear to 
change their practices.
I did not have a problem about douching because they told 
me that it is not good to insert your finger in your vagina. 
(Participant #26)
Adhering to consistent condom use was the greatest 
adherence challenge for women, although whether this was 
in the context of general transmission prevention or to avoid 
genital sample contamination was not detailed by  participants. 
Among those who struggled with adherence to condom use, 
women indicated that partners suggested that condom use 
implied a lack of trust, as illustrated by Participant #11 who 
stated: ‘Yes I did have a problem with my partner – he did 
not want to use condoms. When I asked him to use condoms, 
he said it means I do not trust him, you see.’
In some instances women chose to frame discussions 
of condom use within the requirements of the study and 
being necessary for their health. These women appeared to 
have some success with increasing condom use within their 
partnerships.
Yes, it helped me because sometimes he [partner] would 
want to have sex with me without using a condom. After 
coming here it helped me because since I told him we must 
use a condom when we have sex he listens to me and I also 
take my pills nicely… The thing that helped me too much 
is to use a condom because I did not have any infections. 
When my husband wanted to have sex with me I said we 
must use a condom and before he used to say today we must 
not use a condom. Then I would agree with him, because 
I told myself that we are both HIV positive so it’s better 
that we just finish ourselves. But after getting these pills 
and when the sister explained to me, then I learned more 
that you can prevent some of the things that will harm you. 
(Participant #10)
Others noted that the information they received dur-
ing study visits empowered them to make decisions about 
their health and were therefore able to end relationships in 
which partners remained unwilling to use condoms, such 
as Participant #12 who indicated: ‘It was a problem, that is 
why I stopped seeing him because he did not want to use 
a condom, and he did not believe me, he was saying I am 
telling him lies. I realized that if he does not want to use a 
condom he is going to re-infect me so it’s better that we stop 
seeing each other.’
Discussion and conclusion
This study confirms observations in the randomized, double-
blind, placebo-controlled trial that adherence to the study 
visit schedule, study product, and protocol requirements 
was generally very high. The measures used for recording 
product adherence during the trial were complementary in 
the information that they provided and were corroborated 
during in-depth interviews with participants after the trial. 
Ultimately, the outcomes observed in the trial confirm that 
the adherence levels reported during the trial are likely to 
be reliable.15
Evidence from the interviews reinforced the notion of 
participant agency through using the trial to take control 
of their health and to access optimal health care in a setting 
of uncertain health care quality. This participation motiva-
tion explains the high levels of product adherence seen in 
both arms of the study. Much has been written about the 
poor quality of health care in the South African public 
 sector, specifically with regard to the attitude of health care 
providers.16,17 Participants in this trial made use of the avail-
ability of well-trained and accessible staff to gain information 
about their disease status and to effectively manage their HIV 
prior to initiating antiretroviral therapy. Qualitative research 
with women participating in other HIV prevention trials has 
highlighted the importance of access to good quality health 
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care and caring staff as motivators for trial participation,18,19 
although this study is the first to tie these aspects to good 
adherence.
Participation in clinical trials creates uncertainty through 
the use of drugs with unknown efficacy or an inability to 
determine whether one is receiving the active or placebo 
drug.20 In this instance, women understood that they might 
be receiving an inactive product, yet were willing to engage 
with the trial nonetheless. Aciclovir for the suppression of 
herpes was not available in the South African public health 
sector at the time of this study and while participation may 
have reflected a need to access long-term HSV-2 treatment, 
participation in the trial went beyond access to a single drug. 
Rather, participation was premised on access to good health 
care in the context of HIV more generally.
Concerns that women would abuse reimbursements, fab-
ricate data, share pills, or dump pills do not seem to have been 
confirmed. Women appeared to have been honest about their 
adherence limitations, particularly with regard to condom 
use. Results may have been different had the trial targeted 
primary HIV prevention, although barriers to condom use are 
significant even with intensive safer sex counseling resources 
allocated to clinical trials.21,22 While the negative influence 
of partners on condom use should not be underestimated, in 
this context, condom use adherence may not have resonated 
with women’s desires for health promotion as much as the 
potential to receive aciclovir for the management of their 
herpes infection.
While the limited literature suggests that altruism and 
compensation play a role in study participation,2,4,23 these 
were not primary motivators in this case. Although the key 
outcome of the trial was the prevention of HIV transmission 
through limiting HIV shedding, no participants framed their 
participation in an altruistic desire to prevent further HIV 
transmission.
This study provides further evidence that good adherence 
to daily medication is possible in low and middle income 
countries characterized by poverty and social deprivation. 
High levels of adherence have previously been demonstrated 
for anti-retroviral use in South Africa,24 but this study indi-
cates that high levels of drug adherence for non-life threaten-
ing diseases within the uncertainties of a clinical trial can also 
be achieved when study activities are highly applicable to 
participants or fill an unmet need. While there are additional 
complexities associated with primary HIV prevention trials 
in healthy volunteers, the results of this study bode well for 
trials of pre-exposure prophylaxis (PrEP) in sub-Saharan 
Africa. Additionally, the study highlights adherence as a 
multi-component issue extending beyond study product to 
visits and behaviors associated with trial procedures. The 
study indicates the additional value of conducting multiple 
data collection procedures using different techniques for 
data triangulation.
Limitations
Given that the qualitative component of the study was con-
ducted at the completion of the main clinical trial, the study 
may have excluded women who were lost to follow-up 
in the main study and who may have experienced greater 
barriers to participation. This influence is likely minimal 
given than only 28 women missed their final month 3 visit 
in the trial. Although not supported by the quantitative data 
collected during the trial, there may have been some social 
desirability bias to report higher levels of study adherence 
than actually experienced. Attempts were made to minimize 
this bias through conducting qualitative data collection at the 
end of the trial and using different staff to those involved in 
the collection of trial adherence data.
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